Avidity Biosciences is a technology company.
Avidity Biosciences has raised $16.0M across 1 funding round.
Avidity Biosciences has raised $16.0M in total across 1 funding round.
Avidity Biosciences has raised $16.0M in total across 1 funding round.
Avidity Biosciences's investors include F-Prime Capital Partners.
Avidity Biosciences is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), a novel class of RNA therapeutics that combine monoclonal antibodies' tissue specificity with oligonucleotides' precision to target genetic drivers of diseases, particularly in hard-to-reach tissues like muscle.[1][2][3] It serves patients with rare neuromuscular disorders such as myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD), addressing unmet needs by enabling targeted RNA delivery beyond the liver—where traditional therapies fail.[1][4][5] The company solves the core problem of ineffective RNA therapeutic delivery to non-liver tissues, with three clinical programs advancing (e.g., delpacibart etedesiran or del-desiran in Phase 3 for DM1) and expansion into cardiology and immunology, demonstrating strong growth through partnerships and innovations like improved siRNA durability.[3][4][7]
Avidity Biosciences emerged as a pioneer in RNA delivery innovation, founded to tackle limitations in oligonucleotide therapies by engineering the proprietary AOC platform for targeted delivery to muscle and other tissues.[1][3][6] While specific founder details are not detailed in available sources, the company built its foundation on in-house expertise in antibody engineering, oligonucleotide modulation, and drug delivery, achieving the first-ever successful systemic RNA delivery to muscle in clinical trials.[3][6] Early traction came from unprecedented data across programs for DM1, FSHD, and DMD, leading to FDA designations like Orphan, Fast Track, and Breakthrough Therapy for del-desiran, and pivotal expansion via partnerships in cardiology and immunology.[1][5][7]
Avidity rides the RNA therapeutics revolution, shifting from liver-centric delivery to tissue-agnostic targeting amid rising demand for genetic disease treatments in underserved areas like neuromuscular disorders.[1][2][3] Timing aligns with maturing mAb and oligo technologies, enabling first-in-class therapies for DM1, FSHD, and DMD—diseases lacking disease-modifying options—and fueling market forces like orphan drug incentives and partnerships (e.g., Novartis acquisition interest).[5][7] It influences the ecosystem by validating muscle RNA delivery, inspiring platform expansions, and accelerating pipelines through data-driven innovations that lower off-target risks and improve patient access.[6][8]
Avidity's momentum positions it for transformative milestones, including Phase 3 HARBOR data readouts for del-desiran in DM1 and potential approvals in FSHD/DMD, with pipeline growth in cardiology and immunology via next-gen AOCs.[4][5] Trends like enhanced RNA durability and broader tissue targeting will shape its path, amplified by strategic deals (e.g., Novartis eyeing its late-stage assets).[3][7] Its influence may evolve through acquisitions or partnerships, redefining RNA therapeutics and delivering on the vision to profoundly impact rare disease patients—solidifying its role as a delivery pioneer.[1][2]
Avidity Biosciences has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series B in January 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2017 | $16.0M Series B | F-Prime Capital Partners |